Pharmaceuticals

Key Trends And Drivers In The Bronchodilators Market 2024

The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Impressive Historical Growth

Market Size: Increased from $30.43 billion in 2023 to $32.93 billion in 2024.
CAGR: 8.2%.
Key Drivers:
- Growing geriatric population.
- Rising incidence of asthma.
- Increased funding by government organizations.
- Aging population.
- Increasing air pollution worldwide.

Strong Future Outlook

Expected Growth: Projected to reach $43.25 billion by 2028.
CAGR: 7.0%.
Key Drivers:
- Increasing prevalence of COPD.
- Rising awareness about lung disease treatments.
- Escalating research and development efforts.
- Increased prevalence of pulmonary disorders.
- Rising disposable income.
- Increasing smoking rates.

Key Trends Shaping the Future

Trends:
- Advanced clinical research and innovative strategies.
- Growing technological advancements.
- High prevalence of lung diseases such as COPD and asthma.
- New product launches.
- Rising number of patients with acute respiratory infections.

Rising COPD Prevalence Fuels Growth in Bronchodilator Market

Increasing Prevalence of COPD:
- Chronic obstructive pulmonary disease (COPD) is a progressive lung disease characterized by chronic inflammation of the airways and obstruction or limitation of airflow.
- Bronchodilators are used in COPD to relax the muscles around the airways, helping to open them and make it easier to breathe.
Statistics: According to a report by the Scottish Public Health Observatory, COPD rates increased in males from 83.2 to 97.6 cases per 100,000, and in females from 72.6 to 97.3 as the impact of COVID-19 eased in March 2023.

Major Players in the Bronchodilators Market

Key Companies:
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Hoffmann-La Roche Ltd.
- Bayer AG
- Novartis AG
- Thermo Fisher Scientific
- Abbott Laboratories
- Sanofi S.A.
- GlaxoSmithKline plc
- Siemens Healthcare GmbH
- Merck & Co. Inc.
- AstraZeneca plc
- Teva Pharmaceuticals Industries Ltd.
- Mylan N.V.
- Quest Diagnostics Incorporated.
- Boehringer Ingelheim International GmbH

Lupin Introduces DIFIZMA: A Groundbreaking Fixed-Dose Triple Drug Combination

Innovative Product Launch:
- Major companies in the bronchodilator market are developing innovative products like fixed-dose triple-drug combinations.
- Example: In January 2023, Lupin launched DIFIZMA, a fixed-dose triple-drug bronchodilator with a combination of indacaterol, glycopyrronium, and mometasone for managing asthma.
- DIFIZMA is offered as a dry powder inhalation and is the only fixed-dose combination approved by the Drug Controller General of India (DCGI) for treating inadequately controlled asthma by improving lung function, providing better symptom control, and reducing exacerbations.

AstraZeneca’s Focus on Bronchodilator Products Through CinCor Pharma Acquisition

Strategic Acquisition:
- In February 2023, AstraZeneca plc acquired CinCor Pharma Inc. for $1.8 billion.
- Objective: Develop novel treatments for uncontrolled hypertension and chronic kidney disease and strengthen AstraZeneca’s respiratory portfolio, which includes several bronchodilator products.
- CinCor Pharma: A US-based clinical-stage biopharmaceutical company involved in the development of bronchodilator-related products.

Market Segmentation

By Type:
- Beta-Adrenergic Bronchodilators
- Anticholinergic Bronchodilators
- Xanthine Derivatives
- Other Types.
By Route of Administration:
- Oral
- Nasal (Inhalation)
By Indication:
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Allergic Reactions
- Breathing Problem
- Other Indications.
By End User:
- Hospitals
- Specialty Clinics
- Other End Users.

Regional Insights

You may also like